27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Our findings indicate that quantitative gait measures predict future risk of cognitive decline and dementia in initially non-demented older adults. 4 key findings →
Design: cohort study Participants: 427 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
There is some evidence that multifaceted interventions in hospital reduce the number of falls and that use of hip protectors in care homes prevents hip fractures. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The pathologic indices of Alzheimer disease, cerebrovascular disease, and Lewy body disease accumulate in the brains of older persons with and without dementia, but the extent to which they account for late life cognitive decline remains unknown. 4 key findings →
Design: longitudinal study Participants: 856 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The Honolulu-Asia Aging Study is a longitudinal study of Japanese-American men living in Hawaii. 4 key findings →
Design: longitudinal study Participants: 47 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
From October 2018 to March 2020, 58 participants were recruited (29 per group, 95% [86%-99%]). 5 key findings →
Design: randomized controlled trial Participants: 58 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Higher adherence to the MedDiet was associated with greater gut microbial diversity (p < 0.05) and distinct microbial composition (PERMANOVA, p = 0.001). 5 key findings →
Design: longitudinal study Participants: 746 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The overall adherence rate to MI was 84.7%. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Declines in various cognitive abilities, particularly executive control functions, are observed in older adults. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive training is a popular intervention aimed at attenuating age-related cognitive decline, however, the effects of this intervention on brain structure and function have not been thoroughly explored. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Successfully assisting older adults to maintain or improve cognitive function, particularly when they are dealing with neurodegenerative disorders such as Alzheimer's disease (AD), remains a major challenge. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Intervention participants with MCI self-reported, or demonstrated, improved functioning across a range of cognitive (global cognitive function, executive function, processing speed, memory, attention, mood, emotion, motivation, brain cortex, orientation), and physical (gait, balance, mobility) outcomes. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
The present study investigates whether a combined cognitive and physical training may induce changes in the cortical activity as measured via electroencephalogram (EEG) and whether this change may index a deceleration of pathological processes of brain aging. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The growing prevalence of neurodegenerative disorders associated with aging and cognitive decline has generated increasing cross-disciplinary interest in non-pharmacological interventions, such as computerized cognitive training (CCT), which may prevent or slow cognitive decline. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
It is unclear what non-pharmacological interventions to prevent cognitive decline should comprise. 3 key findings →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source
We examined the effects of cognitive training with elderly participants from the Seattle Longitudinal Study. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The review's analysis confirmed that adherence to the MedDiet is associated with some improvement in cognitive health. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Beyond the well-known effects on cognitive impairment of the Mediterranean diet, a number of studies have investigated the possible action on cognitive decline of different botanicals and phytochemicals, most of which are well-known anti-inflammatory or antioxidant agents with a good tolerability and safety profile. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Of 6,379 citations, 36 articles met inclusion criteria. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Among frail older persons, cognitive training conferred the greatest cognitive benefits. 3 key findings →
Participants: 49 Evidence: low
Full summary, score breakdown and related studies → Original source
Studies suggest that n-3 fatty acids in the diet and adherence to the MedDiet are beneficial in slowing age-related cognitive decline. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Overall, the psychological intervention and cognitive training may be beneficial to cognitive function and psychological well-being. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
In this study, we explored whether several individual self-reported health behaviors were associated with cognitive decline when considered simultaneously, using data from the Wisconsin Registry for Alzheimer's Prevention (WRAP), an Alzheimer's disease risk-enriched cohort who were non-demented and in late midlife at baseline. 5 key findings →
Design: longitudinal study Participants: 828 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Higher visit-to-visit variability in blood pressure independent of average blood pressure was associated with impaired cognitive function in old age. 3 key findings →
Design: cohort study Participants: 5,461 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We examined the impact of physical activity (PA) on longitudinal change in hippocampal volume in cognitively intact older adults at varying genetic risk for the sporadic form of Alzheimer's disease (AD). 2 key findings →
Design: longitudinal study Participants: 24 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study found that a high-intensity multidomain lifestyle intervention did not affect brain biomarker trajectories and was not associated with Aβ pathology, but older adults with specific at-risk brain characteristics, including lower baseline HC volume, showed a greater cognitive benefit of the structured intervention. 4 key findings →
Design: RCT Participants: 983 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
10 of the 1,130 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →